MarketCap
Facebook
X
TelegramCatabasis Pharmaceuticals, Inc. Total Assets 2011-2026 | CATB
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Catabasis Pharmaceuticals, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 47.5 M | 41.8 M | 39.2 M | 17.9 M | 40.2 M | 64.2 M | 16 M | 31 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 64.2 M | 16 M | 37.2 M |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
2.03 B | - | 2.43 % | $ 254 M |  Germany |
 |
AbCellera Biologics
ABCL
|
1.36 B | $ 3.54 | -0.7 % | $ 1.06 B |  Canada |
 |
Acorda Therapeutics
ACOR
|
109 M | - | -24.86 % | $ 820 K |  USA |
 |
Acasti Pharma
ACST
|
72 M | - | 4.01 % | $ 150 M | Canada |
 |
Advaxis
ADXS
|
16.6 M | - | -9.65 % | $ 45.9 M | USA |
 |
AC Immune SA
ACIU
|
231 M | $ 3.25 | 3.83 % | $ 229 M |  Schweiz |
 |
I-Mab
IMAB
|
6.33 B | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
778 M | - | - | $ 1.01 B | USA |
 |
AgeX Therapeutics
AGE
|
12 M | - | -10.17 % | $ 12.2 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
18.1 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
12 M | - | -13.47 % | $ 169 M |  France |
 |
Albireo Pharma
ALBO
|
302 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
62.2 M | - | 10.36 % | $ 9.8 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
15.2 M | - | -1.52 % | $ 24.7 M | USA |
 |
ADC Therapeutics SA
ADCT
|
529 M | $ 4.16 | -1.42 % | $ 105 M | Schweiz |
 |
Aptorum Group Limited
APM
|
16.1 M | $ 0.8 | 1.81 % | $ 4.36 M | China |
 |
Midatech Pharma plc
MTP
|
14.8 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
argenx SE
ARGX
|
6.2 B | $ 712.23 | 1.27 % | $ 25 B |  Niderland |
 |
Adverum Biotechnologies
ADVM
|
180 M | - | - | $ 86.2 M | USA |
 |
Ascendis Pharma A/S
ASND
|
1.3 B | $ 228.93 | -0.91 % | $ 5 B |  Danmark |
 |
Alterity Therapeutics Limited
ATHE
|
41.4 M | $ 3.39 | -6.09 % | $ 8.16 B |  Australia |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.7 M | - | - | $ 26.5 M | USA |
 |
Applied Molecular Transport
AMTI
|
107 M | - | - | $ 10.1 M | USA |
 |
Atea Pharmaceuticals
AVIR
|
315 M | $ 6.15 | 1.57 % | $ 501 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
271 M | $ 6.62 | -0.15 % | $ 181 M |  Israel |
 |
BioCardia
BCDA
|
2.99 M | $ 1.35 | 6.29 % | $ 28.6 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.51 B | - | - | - |  Russia |
 |
Akero Therapeutics
AKRO
|
826 M | - | - | $ 3.67 B | USA |
 |
Athersys
ATHX
|
60.2 M | - | 3.77 % | $ 22.4 M | USA |
 |
Akouos
AKUS
|
279 M | - | 0.23 % | $ 488 M | USA |
 |
Acer Therapeutics
ACER
|
11.6 M | - | 2.71 % | $ 14 M | USA |
 |
ARCA biopharma
ABIO
|
396 M | - | 1052.0 % | $ 415 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
34.8 M | - | 3.16 % | $ 1.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
35.1 M | - | 5.93 % | $ 314 M | Canada |
 |
AlloVir
ALVR
|
119 M | - | 4.14 % | $ 49.1 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
9.12 M | $ 3.58 | -0.28 % | $ 7.79 B | Israel |
 |
Catalyst Biosciences
CBIO
|
166 M | $ 11.29 | -2.51 % | $ 1.01 B | USA |
 |
Anika Therapeutics
ANIK
|
271 M | $ 14.58 | 1.53 % | $ 214 M | USA |
 |
Aptinyx
APTX
|
66.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aptose Biosciences
APTO
|
10.1 M | - | -45.71 % | $ 1.2 M | Canada |
 |
CNS Pharmaceuticals
CNSP
|
8.7 M | $ 2.32 | -5.51 % | $ 887 K | USA |
 |
AVEO Pharmaceuticals
AVEO
|
105 M | - | - | $ 521 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.77 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
124 M | $ 2.69 | 1.7 % | $ 16.9 M | USA |
 |
Curis
CRIS
|
41.3 M | $ 0.89 | 3.74 % | $ 5.61 M | USA |
 |
Avenue Therapeutics
ATXI
|
2.67 M | - | -52.27 % | $ 4.45 M | USA |
 |
BioNTech SE
BNTX
|
22 B | $ 93.04 | 2.76 % | $ 27.2 B | Germany |
 |
Autolus Therapeutics plc
AUTL
|
783 M | $ 1.51 | -0.33 % | $ 385 M | Britain |
 |
Athira Pharma
ATHA
|
58.8 M | - | - | $ 269 M | USA |
 |
CureVac N.V.
CVAC
|
1.16 B | - | - | $ 867 M | Germany |